Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


England Sees Past Price Tag To Back GSK Bubble Baby Gene Therapy

Executive Summary

The cost of Strimvelis for treating severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) is €594,000 but NICE has confirmed that it thinks the benefits of GSK's gene therapy, administered at a hospital in Milan, represents a fair price.


Related Content

Orchard Raises Another $150m For Gene Therapy Pot
Double First At UK HTA NICE For Strimvelis, GSK’s ‘Bubble Baby’ Gene Therapy
Spark's Luxturna Approval Ushers In A New Gene Therapy Era
Walmsley Shakes Up GSK; Cuts More Than 30 Drug Development Programs


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts